JALSG ASH抄録記録 【調整中】
【抄録タイトル///全著者名///掲載誌】 （2016/2/8更新）
62．Toru Sakura, Fumihiko Hayakawa, Isamu Sugiura, Kiyotoshi Imai,
Noriko Usui, Shin Fujisawa, Tohru Murayama, Toshiaki Yujiri, Hitoshi
Kiyoi, Kazunori Ohnishi, Yasushi Miyazaki, Shigeki Ohtake, Yukio
Kobayashi, Keitaro Matsuo, Tomoki Naoe/// Effectiveness of High-Dose
MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG
ALL202-O/// Blood 2015 126:79
61．Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura,
Yoshio Saburi, Yasuhiko Miyata, Yoshihiro Hatta, Fumihiko Kimura,
Satoru Takada, Tetsuya Fukuda, Katsumichi Fujimaki, Maho Ishikawa,
Itaru Matsumura, Noriko Usui, Kensuke Usuki, Yukio Kobayashi, Tomoki
Naoe/// Around 70% of Japanese CML Patients Could Stop Imatinib
According to a-STIM Criteria: The JALSG-STIM213 Study/// Blood 2015
126:4035
60．Miwa Adachi, Akihiro Takeshita, Tomohiko Taki, Shigeki Ohtake,
Katsuji Shinagawa, Hitoshi Kiyoi, Mitsuhiro Matsuda, Masatomo Takahashi,
Nobuhiko Emi, Yukio Kobayashi, Koichi Miyamura, Hiroyuki Fujita,
Toru Sakura, Masako Iwanaga, Noriko Usui, Shuichi Miyawaki, Norio Asou,
Kazunori Ohnishi, Yasushi Miyazaki, Tomoki Naoe/// Prognostic Impact of
Chromosomal Variation in Patients with Acute Promyelocytic Leukemia (APL);
Analysis of 775 Cases Enrolled in the Japan Adult Leukemia Study Group
APL Studies/// Blood 2014 124:2329
59．Shin Fujisawa, Keitaro Matsuo, Shuichi Mizuta, Hideki Akiyama,
Yasunori Ueda, Yasutaka Aoyama, Yoshihiro Hatta, Kazuhiko Kakihana,
Nobuaki Dobashi, Isamu Sugiura, Yasushi Onishi, Tomoya Maeda,
Kiyotoshi Imai, Shigeki Ohtake, Yasushi Miyazaki, Kazunori Ohnishi,
Tomoki Naoe/// Imatinib-Based Chemotherapy for Newly Diagnosed BCR–ABL
Positive Acute Lymphoblastic Leukemia: Japan Adult Leukemia Study
Group (JALSG) Ph+ALL208 Study/// Blood 2014 124:932
58．N Iriyama, N Asou, T Sakura, TMaeda, H Handa, M Takahashi,
S Ohtake, Y Hatta, H Sakamaki, S Honda, Y Miyazaki, S Miyawaki,
M Taniwaki, T Taki, S Yamaguchi, S Satou and T Naoe /// Normal
Karyotype-Acute Myeloid Leukemia With The CD4- CD7+ CD15+ CD34+
Immunophenotype Is a Clinically Distinct Entity With a Favorable
Outcome /// Blood 2013 122:2608
57．K Ishiyama, S Ohtake, H Sakamaki, Y Miyazaki, S Miyawaki,
K Ohnishi, and T Naoe./// Outcomes Of Allogeneic Hematopoietic Stem
Cell Transplantation In AML Patients Registered In Prospective Studies:
The JALSG Experience./// Blood 2013 122:2112
56．T Ono, A Takeshita, K Shinagawa,Y Kishimoto, H Kiyoi, M Okada,
T Yamauchi, N Emi, H Fujita, M Matsuda, F Monma, S Ohtake, CNakaseko,
M Takahashi,Y Kimura, M Iwanaga, N Asou, and T Naoe./// Long-Term
Outcome Of Acute Promyelocytic Leukemia (APL) With Lower Initial
Leukocyte Counts By Using All-Trans Retinoic Acid (ATRA) Alone For
Remission Induction Therapy: Japan Adult Leukemia Study Group (JALSG)
APL97 Study. /// Blood 2013 22:3950
55．K Shinagawa, S Ohtake, T Sakura, Y Ueda, M Sawa, J Miyatake,
N Usui, M Onitsuka, Y Hatta, N Emi, S Tamaki, Y Ito, T Murayama, H Fujita,
K Fujimaki, N Asou, A Takeshia, Y Miyazaki, S Miyawaki, K Ohnishi,
T Naoe, and R Ohno./// A Phase III Study of New Synthetic Retinoid Tamibarotene
(Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed
Acute Promyelocytic Leukemia(APL) : Japa Adult Leukemia Study Group
(JALSG) APL204 Study./// Blood(ASH Annual Meeting Abstracts), Nov
2012;120:410.
54．T Taki, H J Kim, S Ohtake, B S Cho, H Kiyoi, W S Min, Asou, S Y Choi,
Y Miyazaki, Y K Kim, H Sakamaki, J W Cheong, S Honda, S Miyawaki,
M Taniwaki, H J Kim, T Naoe, and Y H Min./// Incidence and Clinical
Features of Core Binding Factor Acute Myeloid Leukemia: A Collaborative
Study of the Japan Adult Leukemia Study Group and the Korean Society
of Hematology./// Blood(ASH Annual Meeting Abstracts), Nov 2012;
120:2584.
53．N Iriyama, Y Hatta, J Takeuchi, Y Ogawa, S Ohtake, T Sakura,
K Mitani, F Ishida, M Takahashi, T Maeda, T Izumi, H Sakamaki,
MS Miyawaki, S Honda, Y Miyazaki, T Taki, M Taniwaki, and T Naoe///
Expression of CD56 Is an Independent Prognostic Factor to Predict
Relapse in Acute Myeloid Leukemia with t(8;21): Results of Japan
Adult Leukemia Study Group(JALSG) AML97 Protocol./// Blood
(ASH Annual Meeting Abstracts), Nov 2012; 120:2511.
52．T Sakura, F Hayakawa, T Yujiri, Y Aoyama, E Kondo, K Fujimaki,
Y Ueda, S Ohtake, Y Miyazaki, S Miyawaki, K Ohnishi, and T Naoe///
Outcome of Pediatric-Type Therapy for Philadelphia Chromosome-
Negative Acute Lymphoblastic Leukemia(ALL) in Adolescents and
Young Adults(AYA): A Study by the Japan Adult Leukemia Study
Group(JALSG ALL202-U study) /// Blood(ASH Annual Meeting
Abstracts), Nov 2012; 120: 1464.
51．S Yamaguchi, E Iwanaga, K Tokunaga, T Nanri, H Suzushima, T
Shimomura, H Mitsuya, and Norio Asou. ///IDH2 Mutations Have
An Unfavorable Impact in Elderly Patients with Acute Myeloid
Leukemia. ///Blood (ASH Annual Meeting Abstracts), Nov 2011;
118: 2519.
50．H Fujita, N Asou, M Iwanaga, R Hyo, S Nomura, H Kiyoi, M Okada,
M Tsuzuki, M Matsuda, T Yamauchi,S Ohtake, T Izumi, C Nakaseko,
K Mitani, K Shinagawa, A Takeshita, Y Miyazaki, K Ohnishi, S
Miyawaki,and Tomoki Naoe. ///Role of Hematopoietic Stem Cell
Transplantation As Salvage Treatment of Acute Promyelocytic
Leukemia Initially Treated with All-Trans-Retinoic Acid: A
Retrospective Analysis of the Japan Adult Leukemia Study Group
(JALSG) APL97 Study ///Blood (ASH Annual Meeting Abstracts),
Nov 2011; 118: 2036.
49．T Ono,A Takeshita, Y Kishimoto, H Kiyoi, M Okada, T Yamauchi, M
Tsuzuki, K Horikawa, M Matsuda, K Shinagawa, F Monma, S
Ohtake, C Nakaseko, M Takahashi, F Yagasaki, Y Kimura, H Fujita,
M Iwanaga, N Asou, K Ohnishi, and Tomoki Naoe. ///Clinical
Features and Prognostic Impact of CD56 Expression in Acute
Promyelocytic Leukemia: Long Term Follow up Data From the
Japan Adult Leukemia Study Group(JALSG) APL97 ///Blood
(ASH Annual Meeting Abstracts), Nov 2011; 118: 3608.
48．A Takeshita, T Ono, Y Kojima,T Kyo, N Asou, H Suzushima, F
Yagasaki, T Maeda,M Okada, C Nakaseko, H Kanbayashi, M
Yamaguchi, M Kurosawa,K Tsuboi, T Yujiri, Y Nannya, N Uike, N
Akiyama, T Fukuda, K Karimata, H Okumura, T Eto, K Izumiyama, A
Watanabe, N Aotsuka, K Ito, K Ozaki, and Tomoki Naoe.
///Efficacy of Gemtuzumab Ozogamicin (GO) Monotherapy on
Relapsed/Refractory Acute Promyelocytic Leukemia (APL)
///Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 1532.
47．S Kako, S Morita, H Sakamaki, H Iida, M Kurokawa, K Miyamura, H
Kanamori, M Hara, N Kobayashi, Y Morishima, K Kawa, T Kyo, T
Sakura, I Jinnai, J Takeuchi, Y Miyazaki, S Miyawaki, K Ohnishi, T
Naoe, and Y Kanda ///A Decision Analysis of Unrelated
Hematopoietic Stem Cell Transplantation for Adult Patients with
Philadelphia Chromosome-Negative Acute Lymphoblastic
Leukemia In First Remission Who Lack An HLA-Matched Sibling
///Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3527.
46．T Ono, A Takeshita, Y Kishimoto, H Kiyoi, M Okada, Y Kawai, M
Tsuzuki, K Horikawa, M Matsuda, K Shinagawa, F Monma, S
Ohtake, C Nakaseko, M Takahashi, F Yagasaki, Y Kimura, M
Iwanaga, N Asou, T Naoe, and R Ohno ///Clinical Features and
Outcomes of Elderly Patients with Acute Promyelocytic Leukemia
(APL) – the Japan Adult Leukemia Study Group APL97 Study.
///Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 1077.
45．H Shimizu, T Saitoh, T Hoshino, N Hatsumi, S Takada, H Irisawa, A
Yokohama, T Jimbo, H Handa, T Matsushima, T Sakura, N
Tsukamoto, M Karasawa, H Murakami, and S Miyawaki ///Clinical
Significance of Granulocytic Sarcoma at Relapse In Adult Patients
with Acute Myeloid Leukemia ///Blood (ASH Annual Meeting
Abstracts), Nov 2010; 116: 4373.
44．C Nakaseko, K Ohnishi, J Takeuchi, S Fujisawa, T Nagai, S Ohtake,
H Yamazaki, T Tauchi, K Imai, N Mori, F Yagasaki, H Akiyama, Y
Maeda, N Usui, Y Saburi, T Ishida, H Kosugi, K Miyamura, Y
Miyazaki, H Handa, A Yokota, K Matsumoto, K Fujimaki, T Matsui, H
Kiyoi, S Miyawaki, R Ohno, and T Naoe ///Sustained Superior
Long-Term Outcomes of Imatinib Therapy In Japanese Patients
with Newly Diagnosed Chronic Myelogenous Leukemia In Chronic
Phase: Sub-Analysis According to the Mean Daily Dose of Imatinib
and the Plasma Trough Levels In JALSG CML202 Study After 66
Months Follow-up. ///Blood (ASH Annual Meeting Abstracts), Nov
2010; 116: 3417.
43．Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H,
Kobayashi Y, Fujisawa S, Yagasaki F, Nishii K, Kiguchi T, Miyazaki Y,
Ohtake S, Miyawaki S, Ohno R, Naoe T, and Ohnishi K. ///A Phase
I/II Trial of Gemtuzumab Ozogamicin in Combination with
Cytarabine and Anthracyclines (Daunorubicin or Idarubicin) for
CD33-Positive Refractory or Relapsed AML Patients Younger
Than 65 Years. Results of Phase I Parts of the JALSG-AML206
Study. ///Blood (ASH Annual Meeting Abstracts), Nov 2009; 114:
4145.
42．Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura
H, Ueda Y, Kishimoto Y, Yagasaki F, Takeuchi J, Iwanaga M,
Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, and Ohno R
///Outcome by Treatment Including An Intensified Consolidation
Program with Dose-Escalated Doxorubicin for Newly Diagnosed
Acute Lymphoblastic Leukemia (ALL): A Study by the Japan Adult
Leukemia Study Group (JALSG ALL97 study). ///Blood (ASH
Annual Meeting Abstracts), Nov 2009; 114: 4334.
41．Miyawaki S, Hatsumi N, Yamauchi T, Tsuboi K, Fujieda A, Takeshita
A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M,
Doki N, Ohnishi K, Naoe T, and Ohno R ///Phase 2 Study of
FLAGM (Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for
Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report
From the Japan Adult Leukemia Study Group (JALSG). ///Blood
(ASH Annual Meeting Abstracts), Nov 2009; 114: 1058.
40．Promising Outcome of Imatinib-Combined Chemotherapy Followed
by Allogeneic Hematopoietic Stem Cell Transplantation for
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
Results of the Japan Adult Leukemia Study Group (JALSG)
Ph+ALL202 Regimen. ///Hatta Y, Mizuta S, Ohtake S, Sugiura I,
Ueda Y, Kanamori H, Akiyama H, Takeuchi M, Usui N, Yujiri T,
Fujieda A, Kiguchi T, Jinnai I, Naoe T, and Ohno R ///Blood (ASH
Annual Meeting Abstracts), Nov 2009; 114: 3090.
39．Updated Results of JALSG AML201 Study Comparing Intensified
Daunorubicin with Idarubicin in Patients with De Novo Acute
Myeloid Leukemia: Effect of Hematopoietic Stem Cell
Transplantation./// Ohtake S, Miyawaki S, Fujita H, Kiyoi H,
Shinagawa K, Usui N, Miyamura K, Nishimura M, Miyazaki Y, Nishii
K, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura
Y, Asou N, Honda S, Ohnishi K, Naoe T, and Ohno R.///Blood (ASH
Annual Meeting Abstracts), Nov 2008; 112: 2171.
38．A Randomized Trial Comparing Individualized Vs. Non-Individualized
Treatment for Elderly Acute Myeloid Leukemia: JALSG GML200
Study/// Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H,
Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H,
Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R,
and Ohno R.///Blood (ASH Annual Meeting Abstracts), Nov 2008;
112: 2961.
37．Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation
during First Complete Remission Following Imatinib-Combined
Chemotherapy in Patients with Philadelphia Chromosome-Positive
Acute Lymphoblastic Leukemia./// Mizuta S, Yanada M, Sugiura I,
Yagasaki F, Yujiri T, Takeuchi M, Hatta Y, Kimura Y, Ueda Y,
Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Jinnai I,
Matsuo K, Naoe T, and Ohno R.///Blood (ASH Annual Meeting
Abstracts), Nov 2008; 112: 462.
36．Long-Term Follow-up of the Randomized JALSG AML 201 Study
Comparing High Dose Ara-C Therapy with Conventional
Consolidation Therapy in Adult Acute Myeloid Leukemia
(AML)///Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K,
Usui N, Miyamura K, Nishimura M, Miyazaki Y, Nishii K, Tadashi
Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y,
Asou N, Honda S, Ohnishi K, Naoe T, and Ohno R.///Blood (ASH
Annual Meeting Abstracts), Nov 2008; 112: 135.
35．Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with
Acute Myelogenous Leukemia (AML). Final Analysis of JALSG
AML97 Study/// Sakamaki H, Miyawaki S, Ohtake S, Emi N,
Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N,
Takahashi M, Ogawa Y, Honda S, and Ohno R.///Blood (ASH
Annual Meeting Abstracts), Nov 2008; 112: 347.
34．Factors associated with relapse-free survival in patients with
Philadelphia chromosome-positive acute lymphoblastic leukemia
treated with imatinib-combined chemotherapy /// Yanada M.
Takeuchi J. Sugiura I. Akiyama H. Usui N. Yagasaki F. Nishii K. Ueda
Y. Takeuchi M. Miyawaki S. Maruta A. Narimatsu H. Miyazaki Y.
Ohtake S. Jinnai I. Matsuo K. Naoe T. Ohno R. /// BLOOD 110
(11):827A-828A 2813 2007
33．Randomized clinical trial of induction therapy comparing intensified
daunorubicin with idarubicin in patients with previously untreated
de novo acute myeloid leukemia (JALSG AML201 study). ///
Ohtake S. Miyawaki S. Fujita H. Kiyoi H. Shinagawa K. Usui N.
Miyamura K. Nishimura M. Miyazaki Y. Nishii K. Nagai T. Yamane T.
Taniwaki M. Takahashi M. Yagasaki F. Kimura Y. Asou N. Honda S.
Ohnishi K. Naoe T. Ohno R. /// BLOOD 108 (11):566A-566A 2000
2006
32．Detection of BCR-ABL transcript by quantitative real-time PCR
and Amp-CML (Transcript mediated amplification) during imatinib
therapy for chronic myeloid leukemia. /// Miyamura K. Yagasaki F.
Kyo T. Ohnishi K. Naoe T. Takeuchi J. Nishimura M. Fujiwara S.
Tauchi T. Ohno R. /// BLOOD 108 (11):282B-282B 4791 2006
31．Postremission therapy in adult acute myeloid leukemia (AML): A
randomized comparison between high dose ara-C therapy and
conventional consolidation therapy (JALSG AML 201 study). ///
Miyawaki S. Ohtake S. Fujisawa S. Kiyoi H. Shinagawa K. Usui N.
Miyamura K. Nishimura M. Miyazaki Y. Nishii K. Nagai T. Yamane T.
Taniwaki M. Takahashi M. Yagasaki F. Kimura Y. Asou N. Honda S.
Ohnishi K. Naoe T. Ohno R. /// BLOOD 108 (11):567A-567A 2005
2006
30．A randomized study with or without intensified maintenance
chemotherapy in patients with acute promyelocytic leukemia who
had become negative for PML-RAR alpha transcript after
consolidation therapy: The Japan adult leukemia study group
(JALSG) APL97 study. /// Asou N. Kishimoto Y. Kiyoi H. Okada M.
Kawai Y. Tsuzuki M. Horikawa K. Matsuda M. Shinagawa K.
Kobayashi T. Ohtake S. Nishimura M. Takahashi M. Yagasaki F.
Takeshita A. Kimura Y. Iwanaga M. Naoe T. Ohno R. /// BLOOD
108 (11):569A-569A 2009 2006
29．High complete remission rate and promising outcome by
combination of imatinib and chemotherapy for newly diagnosed
BCR-ABL-positive acute lymphoblastic leukemia /// Yanada M.
Takeuchi J. Sugiura I. Akiyama H. Usui N. Yagasaki F. Emi N.
Miyazaki Y. Ohtake S. Jinnai I. Matsuo K. Naoe T. Ohno R. ///
BLOOD 106 (11):520A-520A 1827 2005
28．Pharmacokinetics of arsenic species with relapsed or refractory
acute promyelocytic leukemia (APL) treated with arsenic trioxide
(ATO) in Japanese patients. /// Shigeno K. Kobayashi M. Sahara
N. Nakamura S. Fujisawa S. Naito K. Shinjo K. Takeshita A. Ohno R.
Kinoshita K. Shimoya M. Kaise T. Ohnishi K. /// BLOOD 106
(11):185B-185B 4426 2005
27．A new scoring system to predict the prognosis of patients with
acute myeloid leukemia. Study from the Japan Adult Leukemia
Study Group. /// Miyazaki Y. Nishida K. Kuriyama K. Taniwaki M.
Sakamaki H. Miyawaki S. Ohtake S. Honda S. Tomonaga M. Ohno R.
/// BLOOD 106 (11):667A-668A 2373 2005
26．Triphasic exponential decline of BCR-ABL transcripts during
imatinib therapy for chronic myelogenous leukemia. /// Miyamura
K. Ohnishi K. Naoe T. Takeuchi J. Yoshiki N. Yagasaki F. Fujisawa S.
Kimura Y. Motoji T. Imai K. Yamane T. Yoshida S. Miyawaki S.
Saburi Y. Kitamura K. Ohno R. /// BLOOD 106 (11):322A-322A
1107 2005
25．Prognosis of acute myeloid leukemia with translocation (8;21): A
survey of 142 cases investigated in the JALSG AML97 study. ///
Hatsumi N. Miyawaki S. Sakamaki H. Ohtake S. Yagaski F.
Mitani K. Matsuda S. Kishimoto Y. Miyazaki Y. Asou N. Honda S. Taniwaki M.
Ohno R. /// BLOOD 106 (11):206B-206B 4511 2005
24．Combination of intensive chemotherapy and imatinib (IDEAMOP
regimen) for the treatment of newly diagnosed BCR-ABL positive
acute lymphoblastic leukemia; Excellent efficacy without increasing
toxicity. /// Yanada M. Emi N. Usui N. Takeuchi J. Sugiura I.
Takeuchi M. Kobayashi T. Yagasaki F. Ohtake S. Matsuo K. Naoe T.
Ohno R. Japan Adult Leukemia Study Grp /// BLOOD 104
(11):748A-748A 2736 2004
23．P-glycoprotein is related to the achievement of complete
remission but not to disease-free survival in adult acute
lymphoblastic leukemia: A prospective analysis in the
JALSG-ALL97 study /// Takeshita A. Ohnishi K. Miyazaki Y. Jnnai
I. Miyawaki S. Takahashi M. Murakami T. Inoue N. Tanaka J. Asou
N. Kobayashi Y. Ueda R. Ohno R. /// BLOOD 104 (11):311A-311A
1095 2004
22．Postremission treatment with chemotherapy or allogeneic stem
cell transplantation (allo-SCT) in adults with acute myeloid
leukemia (AML) – JALSG AML-97 trial. /// Sakamaki H. Miyawaki
S. Kishimoto Y. Miyazaki Y. Asou N. Ogawa Y. Honda S. Ohno R.
/// BLOOD 104 (11):632A-632A 2298 2004
21．Postremission therapy in adult acute myeloid leukemia (AML): A
randomized comparison of intensified consolidation therapy without
maintenance therapy against conventional consolidation with
maintenance therapy -JALSG AML-97 trial. /// Miyawaki S.
Ohtake S. Yagasaki F. Mitani K. Matsuda S. Kishimoto Y. Miyazaki
Y. Asou N. Ogawa Y. Honda S. Ohno R. /// BLOOD 104
(11):248A-248A 868 2004
20．Validation study on the prediction of response to imatinib mesylate
in chronic myeloid leukemia (CML) patients by genome-wide cDNA
microarray analysis. /// Kagami Y. Katagiri T. Kaneta Y. Tsuruo T.
Nakamura Y. Ohno R. /// BLOOD 104 (11):805A-805A 2946 2004
19．Prospective study of P-glycoprotein, multidrug resistance
associated protein and lung resistance related protein expression
in acute myeloid leukemia treated with the JALSG-AML95
protocol. /// Takeshita A. Shinjo K. Ohnishi K. Miyawaki S.
Kishimoto Y. Okada M. Mitani K. Asou N. Komatsu N. Kobayashi Y.
Jinnai I. Ohtake S. Ueda R. Ohno R. /// BLOOD 102
(11):605A-605A 2233 2003
18．Biological and clinical significance of the FLT3 transcript level in
acute myeloid leukemia. /// Ozeki K. Kiyoi H. Ueda R. Ohno R. Emi
K. Naoe T. /// BLOOD 102 (11):575A-576A 2119 2003
17．Cytogenetic heterogeneity of acute myeloid leukemia with
trilineage dysplasia – JALSG-AML 92 study. /// Tomonaga M.
Kuriyama K. Miyazaki Y. Miyawaki S. Ohtake S. Sakamaki H.
Matsuo T. Emi N. Kobayashi T. Matsushima T. Shinagawa K. Ohno
R. /// BLOOD 100 (11):335A-335A 1298 2002
16．Arsenic trioxide therapy for relapsed or refractory Japanese
patients with acute promyelocytic leukemia /// Shigeno K.
Nakamura S. Naito K. Yoshida H. Fujisawa S. Shinjo K. Fujita Y.
Matsui H. Sahara N. Takeshita A. Ohno R. Ohnishi K. /// BLOOD
100 (11):264B-264B 4583 2002
15．The percentage of myeloperoxidase-positive blast cells is a strong
independent prognostic factor in acute myeloid leukemia, even in
the patients with normal karyotype – JALSG-AML92 study. ///
Miyazaki Y. Matsuo T. Kuriyama K. Yoshida S. Tomonaga M. Emi N.
Kobayashi T. Miyawaki S. Matsushima T. Shinagawa K. Honda S.
Ohno R. /// BLOOD 100 (11):334A-334A 1297 2002
14．Myeloid/NK cell precursor acute leukemia is a distinct subtype of
AML M0. /// Suzuki R. Murata M. Kami M. Ohtake S. Asou N.
Kodera Y. Seto M. Hamajima N. Shimoyama M. Ohno R. Morishima
Y. Nakamura S. /// BLOOD 98 (11):460A-460A 1926 Part 1 2001
13．Multicenter prospective study of interferon-alpha versus bone
marrow transplantation for newly diagnosed patients with chronic
myelogenous leukemia: An interim analysis of the Kouseisho
leukemia study group. /// Ohnishi K. Ino T. Kishimoto Y. Usui N.
Shimazaki C. Ohtake S. Ohno R. /// BLOOD 98 (11):348A-348A
1468 Part 1 2001
12．Standard dose of idarubicin and cytarabine is highly effective
remission induction therapy for the patients with therapy-related
leukemia (TRL): A result of multiinstitutional phase II study. ///
Yokozawa T. Takeyama K. Fukushima T. Uike N. Nagata K. Kagami
Y. Ohno R. Saito H. Ueda R. /// BLOOD 94 (10):298A-298A 1329
Part 1 Suppl. 1 1999
11．Good prognosis of patients with acute promyelocytic leukemia
(APL) who obtained second complete remission (CR) by a new
retinoid, AM80, for relapse from CR induced all -trans retinoic
acid. /// Takeshita A. Naito K. Miyawaki S. Takeuchi M. Ueda R.
Ohno R. /// BLOOD 94 (10):506A-506A 2264 Part 1 Suppl. 1 1999
10．Combination chemotherapy with risk factors-adjusted dose
attenuation for high-risk myelodysplastic syndromes and their
leukemia in the japan adult leukemia study group. /// Okamoto T.
Kanamaru A. Shimazaki C. Motoji T. Takemoto Y. Ohno R. Japan
Luekemia Study Grp /// BLOOD 94 (10):307A-307A 1375 Part 1
Suppl. 1 1999
9．Randomized clinical trial of response-oriented individualized versus
fixed schedule induction chemotherapy in adult acute myeloid
leukemia: The JALSG AML95 study. /// Ohtake S. Miyawaki S.
Tanimoto M. Kuriyama K. Matusda S. Hatake K. Kishimoto Y.
Takemoto Y. Takahashi M. Tamura J. Takeuchi J. Kageyama S.
Kanamaru A. Asou N. Ohno R. /// BLOOD 94 (10):298A-298A
1330 Part 1 Suppl. 1 1999
8．The JALSG APL92 study for newly diagnosed acute promyelocytic
leukemia (APL): Analysis of prognostic factors to increase cure
rate in the next study. /// Ohno R. Asou N. Kanamaru A. Miyawaki
S. Ohtake S. Tomonaga M. /// BLOOD 94 (10):505A-505A 2262
Part 1 Suppl. 1 1999
7．Randomized study of individualized induction therapy with or
without etoposide in adult acute myeloid leukemia (except for M3)
(JALSG-AML92 study) and analysis of prognostic factors. ///
Miyawaki S. Tanimoto M. Kobayashi T. Minami S. Tamura J. Hatake
K. Kuriyama K. Ohmoto E.. Saito K. Kanamaru A. Oho H. Ohtake S.
Jinnai I. Sakamaki H. Yamada O. Asou N. Takahashi M. Takeyama
K. Matsuda S. Ueda R. Ohno R. /// BLOOD 90 (10):2244-2244
Part 1 Suppl. 1 1997
6．JALSG-AML92 for newly diagnosed acute promyelocytic leukemia
(APL) with all-trans retinoic acid (ATRA) followed by intensive
consolidation acid maintenance/intensification chemotherapy:
Prognostic factors for remission and survival /// Ohno R. Asou N.
Kanamaru A. Adachi K. Miyawaki S. Kageyama S. Hiraoka A.
Ohmoto E. Sakamaki H. Tsubaki K. Saito K. Kuriyama K. Oh H.
Kitano Y. /// BLOOD 88 (10):1157-1157 Part 1 Suppl. 1 1996
5．Macrophage-colony stimulating factor (M-CSF) reduces the
incidence and duration of febrile neutropenia and shortens the
period required to finish three courses of intensive consolidation
therapy in acute myeloid leukemia (AML): A double-blind controlled
study /// Ohno R. Miyawaki S. Hatake K. Tomonaga M. Kobayashi
T. Tanimoto M. Masaoka T. Miura Y. Takaku F. Ohashi Y. Motoyoshi
K. /// BLOOD 86 (10):1050-1050 1995
4．Is chemotherapy or HLA-identical sibling bone marrow transplant
better in adults with acute lymphoblastic leukemia (ALL) in first
remission?. /// Oh H. Ohno R. Tanimoto M. Tomonaga M. Murakami
H. Ino T. Zhang MJ. Horowitz MM. Gale RP /// BLOOD 86
(10):2456-2456 Suppl. 1 1995
3．Molecular analysis of the t(15;17) translocation in de novo and
secondary acute promyelocytic leukemia /// Naoe T. Kudo K.
Yoshida H. Horibe K. Ohno, R /// BLOOD 86 (10):2933-2933 1995
2．All-trans-retinoic acid for the treatment of newly-diagnosed acute
promyelocytic leukemia-response /// Kanamaru A. Ohno R. ///
BLOOD 86 (4):1645-1645 1995
1．Randomized trial between behenoyl cytarabine (BHAC) or
cytarabine in combination chemotherapy of adult acute myeloid-
leukemia (AML) (JALSG-AML89 protocol) and analysis of
prognostic factors /// Kobayashi T. Miyawaki S. Tanimoto M.
Kuriyama K. Murakami H. Yoshida M. Kodera Y. Minato K. Tsubaki
K. Ohmoto E. Oh H. Jinnai I. Sakamaki H. Hiraoka A. Kanamaru A.
Takahashi I. Furusawa S. NaoeT. Yamada O. Asou N. Nishikawa K.
Okabe K. Ogura M. Tanaka M. Ohno R. /// BLOOD 84
(10):A146-A146 Suppl. 1 1994
Noriko Usui, Shin Fujisawa, Tohru Murayama, Toshiaki Yujiri, Hitoshi
Kiyoi, Kazunori Ohnishi, Yasushi Miyazaki, Shigeki Ohtake, Yukio
Kobayashi, Keitaro Matsuo, Tomoki Naoe/// Effectiveness of High-Dose
MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG
ALL202-O/// Blood 2015 126:79
61．Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura,
Yoshio Saburi, Yasuhiko Miyata, Yoshihiro Hatta, Fumihiko Kimura,
Satoru Takada, Tetsuya Fukuda, Katsumichi Fujimaki, Maho Ishikawa,
Itaru Matsumura, Noriko Usui, Kensuke Usuki, Yukio Kobayashi, Tomoki
Naoe/// Around 70% of Japanese CML Patients Could Stop Imatinib
According to a-STIM Criteria: The JALSG-STIM213 Study/// Blood 2015
126:4035
60．Miwa Adachi, Akihiro Takeshita, Tomohiko Taki, Shigeki Ohtake,
Katsuji Shinagawa, Hitoshi Kiyoi, Mitsuhiro Matsuda, Masatomo Takahashi,
Nobuhiko Emi, Yukio Kobayashi, Koichi Miyamura, Hiroyuki Fujita,
Toru Sakura, Masako Iwanaga, Noriko Usui, Shuichi Miyawaki, Norio Asou,
Kazunori Ohnishi, Yasushi Miyazaki, Tomoki Naoe/// Prognostic Impact of
Chromosomal Variation in Patients with Acute Promyelocytic Leukemia (APL);
Analysis of 775 Cases Enrolled in the Japan Adult Leukemia Study Group
APL Studies/// Blood 2014 124:2329
59．Shin Fujisawa, Keitaro Matsuo, Shuichi Mizuta, Hideki Akiyama,
Yasunori Ueda, Yasutaka Aoyama, Yoshihiro Hatta, Kazuhiko Kakihana,
Nobuaki Dobashi, Isamu Sugiura, Yasushi Onishi, Tomoya Maeda,
Kiyotoshi Imai, Shigeki Ohtake, Yasushi Miyazaki, Kazunori Ohnishi,
Tomoki Naoe/// Imatinib-Based Chemotherapy for Newly Diagnosed BCR–ABL
Positive Acute Lymphoblastic Leukemia: Japan Adult Leukemia Study
Group (JALSG) Ph+ALL208 Study/// Blood 2014 124:932
58．N Iriyama, N Asou, T Sakura, TMaeda, H Handa, M Takahashi,
S Ohtake, Y Hatta, H Sakamaki, S Honda, Y Miyazaki, S Miyawaki,
M Taniwaki, T Taki, S Yamaguchi, S Satou and T Naoe /// Normal
Karyotype-Acute Myeloid Leukemia With The CD4- CD7+ CD15+ CD34+
Immunophenotype Is a Clinically Distinct Entity With a Favorable
Outcome /// Blood 2013 122:2608
57．K Ishiyama, S Ohtake, H Sakamaki, Y Miyazaki, S Miyawaki,
K Ohnishi, and T Naoe./// Outcomes Of Allogeneic Hematopoietic Stem
Cell Transplantation In AML Patients Registered In Prospective Studies:
The JALSG Experience./// Blood 2013 122:2112
56．T Ono, A Takeshita, K Shinagawa,Y Kishimoto, H Kiyoi, M Okada,
T Yamauchi, N Emi, H Fujita, M Matsuda, F Monma, S Ohtake, CNakaseko,
M Takahashi,Y Kimura, M Iwanaga, N Asou, and T Naoe./// Long-Term
Outcome Of Acute Promyelocytic Leukemia (APL) With Lower Initial
Leukocyte Counts By Using All-Trans Retinoic Acid (ATRA) Alone For
Remission Induction Therapy: Japan Adult Leukemia Study Group (JALSG)
APL97 Study. /// Blood 2013 22:3950
55．K Shinagawa, S Ohtake, T Sakura, Y Ueda, M Sawa, J Miyatake,
N Usui, M Onitsuka, Y Hatta, N Emi, S Tamaki, Y Ito, T Murayama, H Fujita,
K Fujimaki, N Asou, A Takeshia, Y Miyazaki, S Miyawaki, K Ohnishi,
T Naoe, and R Ohno./// A Phase III Study of New Synthetic Retinoid Tamibarotene
(Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed
Acute Promyelocytic Leukemia(APL) : Japa Adult Leukemia Study Group
(JALSG) APL204 Study./// Blood(ASH Annual Meeting Abstracts), Nov
2012;120:410.
54．T Taki, H J Kim, S Ohtake, B S Cho, H Kiyoi, W S Min, Asou, S Y Choi,
Y Miyazaki, Y K Kim, H Sakamaki, J W Cheong, S Honda, S Miyawaki,
M Taniwaki, H J Kim, T Naoe, and Y H Min./// Incidence and Clinical
Features of Core Binding Factor Acute Myeloid Leukemia: A Collaborative
Study of the Japan Adult Leukemia Study Group and the Korean Society
of Hematology./// Blood(ASH Annual Meeting Abstracts), Nov 2012;
120:2584.
53．N Iriyama, Y Hatta, J Takeuchi, Y Ogawa, S Ohtake, T Sakura,
K Mitani, F Ishida, M Takahashi, T Maeda, T Izumi, H Sakamaki,
MS Miyawaki, S Honda, Y Miyazaki, T Taki, M Taniwaki, and T Naoe///
Expression of CD56 Is an Independent Prognostic Factor to Predict
Relapse in Acute Myeloid Leukemia with t(8;21): Results of Japan
Adult Leukemia Study Group(JALSG) AML97 Protocol./// Blood
(ASH Annual Meeting Abstracts), Nov 2012; 120:2511.
52．T Sakura, F Hayakawa, T Yujiri, Y Aoyama, E Kondo, K Fujimaki,
Y Ueda, S Ohtake, Y Miyazaki, S Miyawaki, K Ohnishi, and T Naoe///
Outcome of Pediatric-Type Therapy for Philadelphia Chromosome-
Negative Acute Lymphoblastic Leukemia(ALL) in Adolescents and
Young Adults(AYA): A Study by the Japan Adult Leukemia Study
Group(JALSG ALL202-U study) /// Blood(ASH Annual Meeting
Abstracts), Nov 2012; 120: 1464.
51．S Yamaguchi, E Iwanaga, K Tokunaga, T Nanri, H Suzushima, T
Shimomura, H Mitsuya, and Norio Asou. ///IDH2 Mutations Have
An Unfavorable Impact in Elderly Patients with Acute Myeloid
Leukemia. ///Blood (ASH Annual Meeting Abstracts), Nov 2011;
118: 2519.
50．H Fujita, N Asou, M Iwanaga, R Hyo, S Nomura, H Kiyoi, M Okada,
M Tsuzuki, M Matsuda, T Yamauchi,S Ohtake, T Izumi, C Nakaseko,
K Mitani, K Shinagawa, A Takeshita, Y Miyazaki, K Ohnishi, S
Miyawaki,and Tomoki Naoe. ///Role of Hematopoietic Stem Cell
Transplantation As Salvage Treatment of Acute Promyelocytic
Leukemia Initially Treated with All-Trans-Retinoic Acid: A
Retrospective Analysis of the Japan Adult Leukemia Study Group
(JALSG) APL97 Study ///Blood (ASH Annual Meeting Abstracts),
Nov 2011; 118: 2036.
49．T Ono,A Takeshita, Y Kishimoto, H Kiyoi, M Okada, T Yamauchi, M
Tsuzuki, K Horikawa, M Matsuda, K Shinagawa, F Monma, S
Ohtake, C Nakaseko, M Takahashi, F Yagasaki, Y Kimura, H Fujita,
M Iwanaga, N Asou, K Ohnishi, and Tomoki Naoe. ///Clinical
Features and Prognostic Impact of CD56 Expression in Acute
Promyelocytic Leukemia: Long Term Follow up Data From the
Japan Adult Leukemia Study Group(JALSG) APL97 ///Blood
(ASH Annual Meeting Abstracts), Nov 2011; 118: 3608.
48．A Takeshita, T Ono, Y Kojima,T Kyo, N Asou, H Suzushima, F
Yagasaki, T Maeda,M Okada, C Nakaseko, H Kanbayashi, M
Yamaguchi, M Kurosawa,K Tsuboi, T Yujiri, Y Nannya, N Uike, N
Akiyama, T Fukuda, K Karimata, H Okumura, T Eto, K Izumiyama, A
Watanabe, N Aotsuka, K Ito, K Ozaki, and Tomoki Naoe.
///Efficacy of Gemtuzumab Ozogamicin (GO) Monotherapy on
Relapsed/Refractory Acute Promyelocytic Leukemia (APL)
///Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 1532.
47．S Kako, S Morita, H Sakamaki, H Iida, M Kurokawa, K Miyamura, H
Kanamori, M Hara, N Kobayashi, Y Morishima, K Kawa, T Kyo, T
Sakura, I Jinnai, J Takeuchi, Y Miyazaki, S Miyawaki, K Ohnishi, T
Naoe, and Y Kanda ///A Decision Analysis of Unrelated
Hematopoietic Stem Cell Transplantation for Adult Patients with
Philadelphia Chromosome-Negative Acute Lymphoblastic
Leukemia In First Remission Who Lack An HLA-Matched Sibling
///Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3527.
46．T Ono, A Takeshita, Y Kishimoto, H Kiyoi, M Okada, Y Kawai, M
Tsuzuki, K Horikawa, M Matsuda, K Shinagawa, F Monma, S
Ohtake, C Nakaseko, M Takahashi, F Yagasaki, Y Kimura, M
Iwanaga, N Asou, T Naoe, and R Ohno ///Clinical Features and
Outcomes of Elderly Patients with Acute Promyelocytic Leukemia
(APL) – the Japan Adult Leukemia Study Group APL97 Study.
///Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 1077.
45．H Shimizu, T Saitoh, T Hoshino, N Hatsumi, S Takada, H Irisawa, A
Yokohama, T Jimbo, H Handa, T Matsushima, T Sakura, N
Tsukamoto, M Karasawa, H Murakami, and S Miyawaki ///Clinical
Significance of Granulocytic Sarcoma at Relapse In Adult Patients
with Acute Myeloid Leukemia ///Blood (ASH Annual Meeting
Abstracts), Nov 2010; 116: 4373.
44．C Nakaseko, K Ohnishi, J Takeuchi, S Fujisawa, T Nagai, S Ohtake,
H Yamazaki, T Tauchi, K Imai, N Mori, F Yagasaki, H Akiyama, Y
Maeda, N Usui, Y Saburi, T Ishida, H Kosugi, K Miyamura, Y
Miyazaki, H Handa, A Yokota, K Matsumoto, K Fujimaki, T Matsui, H
Kiyoi, S Miyawaki, R Ohno, and T Naoe ///Sustained Superior
Long-Term Outcomes of Imatinib Therapy In Japanese Patients
with Newly Diagnosed Chronic Myelogenous Leukemia In Chronic
Phase: Sub-Analysis According to the Mean Daily Dose of Imatinib
and the Plasma Trough Levels In JALSG CML202 Study After 66
Months Follow-up. ///Blood (ASH Annual Meeting Abstracts), Nov
2010; 116: 3417.
43．Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H,
Kobayashi Y, Fujisawa S, Yagasaki F, Nishii K, Kiguchi T, Miyazaki Y,
Ohtake S, Miyawaki S, Ohno R, Naoe T, and Ohnishi K. ///A Phase
I/II Trial of Gemtuzumab Ozogamicin in Combination with
Cytarabine and Anthracyclines (Daunorubicin or Idarubicin) for
CD33-Positive Refractory or Relapsed AML Patients Younger
Than 65 Years. Results of Phase I Parts of the JALSG-AML206
Study. ///Blood (ASH Annual Meeting Abstracts), Nov 2009; 114:
4145.
42．Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura
H, Ueda Y, Kishimoto Y, Yagasaki F, Takeuchi J, Iwanaga M,
Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, and Ohno R
///Outcome by Treatment Including An Intensified Consolidation
Program with Dose-Escalated Doxorubicin for Newly Diagnosed
Acute Lymphoblastic Leukemia (ALL): A Study by the Japan Adult
Leukemia Study Group (JALSG ALL97 study). ///Blood (ASH
Annual Meeting Abstracts), Nov 2009; 114: 4334.
41．Miyawaki S, Hatsumi N, Yamauchi T, Tsuboi K, Fujieda A, Takeshita
A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M,
Doki N, Ohnishi K, Naoe T, and Ohno R ///Phase 2 Study of
FLAGM (Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for
Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report
From the Japan Adult Leukemia Study Group (JALSG). ///Blood
(ASH Annual Meeting Abstracts), Nov 2009; 114: 1058.
40．Promising Outcome of Imatinib-Combined Chemotherapy Followed
by Allogeneic Hematopoietic Stem Cell Transplantation for
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
Results of the Japan Adult Leukemia Study Group (JALSG)
Ph+ALL202 Regimen. ///Hatta Y, Mizuta S, Ohtake S, Sugiura I,
Ueda Y, Kanamori H, Akiyama H, Takeuchi M, Usui N, Yujiri T,
Fujieda A, Kiguchi T, Jinnai I, Naoe T, and Ohno R ///Blood (ASH
Annual Meeting Abstracts), Nov 2009; 114: 3090.
39．Updated Results of JALSG AML201 Study Comparing Intensified
Daunorubicin with Idarubicin in Patients with De Novo Acute
Myeloid Leukemia: Effect of Hematopoietic Stem Cell
Transplantation./// Ohtake S, Miyawaki S, Fujita H, Kiyoi H,
Shinagawa K, Usui N, Miyamura K, Nishimura M, Miyazaki Y, Nishii
K, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura
Y, Asou N, Honda S, Ohnishi K, Naoe T, and Ohno R.///Blood (ASH
Annual Meeting Abstracts), Nov 2008; 112: 2171.
38．A Randomized Trial Comparing Individualized Vs. Non-Individualized
Treatment for Elderly Acute Myeloid Leukemia: JALSG GML200
Study/// Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H,
Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H,
Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R,
and Ohno R.///Blood (ASH Annual Meeting Abstracts), Nov 2008;
112: 2961.
37．Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation
during First Complete Remission Following Imatinib-Combined
Chemotherapy in Patients with Philadelphia Chromosome-Positive
Acute Lymphoblastic Leukemia./// Mizuta S, Yanada M, Sugiura I,
Yagasaki F, Yujiri T, Takeuchi M, Hatta Y, Kimura Y, Ueda Y,
Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Jinnai I,
Matsuo K, Naoe T, and Ohno R.///Blood (ASH Annual Meeting
Abstracts), Nov 2008; 112: 462.
36．Long-Term Follow-up of the Randomized JALSG AML 201 Study
Comparing High Dose Ara-C Therapy with Conventional
Consolidation Therapy in Adult Acute Myeloid Leukemia
(AML)///Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K,
Usui N, Miyamura K, Nishimura M, Miyazaki Y, Nishii K, Tadashi
Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y,
Asou N, Honda S, Ohnishi K, Naoe T, and Ohno R.///Blood (ASH
Annual Meeting Abstracts), Nov 2008; 112: 135.
35．Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with
Acute Myelogenous Leukemia (AML). Final Analysis of JALSG
AML97 Study/// Sakamaki H, Miyawaki S, Ohtake S, Emi N,
Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N,
Takahashi M, Ogawa Y, Honda S, and Ohno R.///Blood (ASH
Annual Meeting Abstracts), Nov 2008; 112: 347.
34．Factors associated with relapse-free survival in patients with
Philadelphia chromosome-positive acute lymphoblastic leukemia
treated with imatinib-combined chemotherapy /// Yanada M.
Takeuchi J. Sugiura I. Akiyama H. Usui N. Yagasaki F. Nishii K. Ueda
Y. Takeuchi M. Miyawaki S. Maruta A. Narimatsu H. Miyazaki Y.
Ohtake S. Jinnai I. Matsuo K. Naoe T. Ohno R. /// BLOOD 110
(11):827A-828A 2813 2007
33．Randomized clinical trial of induction therapy comparing intensified
daunorubicin with idarubicin in patients with previously untreated
de novo acute myeloid leukemia (JALSG AML201 study). ///
Ohtake S. Miyawaki S. Fujita H. Kiyoi H. Shinagawa K. Usui N.
Miyamura K. Nishimura M. Miyazaki Y. Nishii K. Nagai T. Yamane T.
Taniwaki M. Takahashi M. Yagasaki F. Kimura Y. Asou N. Honda S.
Ohnishi K. Naoe T. Ohno R. /// BLOOD 108 (11):566A-566A 2000
2006
32．Detection of BCR-ABL transcript by quantitative real-time PCR
and Amp-CML (Transcript mediated amplification) during imatinib
therapy for chronic myeloid leukemia. /// Miyamura K. Yagasaki F.
Kyo T. Ohnishi K. Naoe T. Takeuchi J. Nishimura M. Fujiwara S.
Tauchi T. Ohno R. /// BLOOD 108 (11):282B-282B 4791 2006
31．Postremission therapy in adult acute myeloid leukemia (AML): A
randomized comparison between high dose ara-C therapy and
conventional consolidation therapy (JALSG AML 201 study). ///
Miyawaki S. Ohtake S. Fujisawa S. Kiyoi H. Shinagawa K. Usui N.
Miyamura K. Nishimura M. Miyazaki Y. Nishii K. Nagai T. Yamane T.
Taniwaki M. Takahashi M. Yagasaki F. Kimura Y. Asou N. Honda S.
Ohnishi K. Naoe T. Ohno R. /// BLOOD 108 (11):567A-567A 2005
2006
30．A randomized study with or without intensified maintenance
chemotherapy in patients with acute promyelocytic leukemia who
had become negative for PML-RAR alpha transcript after
consolidation therapy: The Japan adult leukemia study group
(JALSG) APL97 study. /// Asou N. Kishimoto Y. Kiyoi H. Okada M.
Kawai Y. Tsuzuki M. Horikawa K. Matsuda M. Shinagawa K.
Kobayashi T. Ohtake S. Nishimura M. Takahashi M. Yagasaki F.
Takeshita A. Kimura Y. Iwanaga M. Naoe T. Ohno R. /// BLOOD
108 (11):569A-569A 2009 2006
29．High complete remission rate and promising outcome by
combination of imatinib and chemotherapy for newly diagnosed
BCR-ABL-positive acute lymphoblastic leukemia /// Yanada M.
Takeuchi J. Sugiura I. Akiyama H. Usui N. Yagasaki F. Emi N.
Miyazaki Y. Ohtake S. Jinnai I. Matsuo K. Naoe T. Ohno R. ///
BLOOD 106 (11):520A-520A 1827 2005
28．Pharmacokinetics of arsenic species with relapsed or refractory
acute promyelocytic leukemia (APL) treated with arsenic trioxide
(ATO) in Japanese patients. /// Shigeno K. Kobayashi M. Sahara
N. Nakamura S. Fujisawa S. Naito K. Shinjo K. Takeshita A. Ohno R.
Kinoshita K. Shimoya M. Kaise T. Ohnishi K. /// BLOOD 106
(11):185B-185B 4426 2005
27．A new scoring system to predict the prognosis of patients with
acute myeloid leukemia. Study from the Japan Adult Leukemia
Study Group. /// Miyazaki Y. Nishida K. Kuriyama K. Taniwaki M.
Sakamaki H. Miyawaki S. Ohtake S. Honda S. Tomonaga M. Ohno R.
/// BLOOD 106 (11):667A-668A 2373 2005
26．Triphasic exponential decline of BCR-ABL transcripts during
imatinib therapy for chronic myelogenous leukemia. /// Miyamura
K. Ohnishi K. Naoe T. Takeuchi J. Yoshiki N. Yagasaki F. Fujisawa S.
Kimura Y. Motoji T. Imai K. Yamane T. Yoshida S. Miyawaki S.
Saburi Y. Kitamura K. Ohno R. /// BLOOD 106 (11):322A-322A
1107 2005
25．Prognosis of acute myeloid leukemia with translocation (8;21): A
survey of 142 cases investigated in the JALSG AML97 study. ///
Hatsumi N. Miyawaki S. Sakamaki H. Ohtake S. Yagaski F.
Mitani K. Matsuda S. Kishimoto Y. Miyazaki Y. Asou N. Honda S. Taniwaki M.
Ohno R. /// BLOOD 106 (11):206B-206B 4511 2005
24．Combination of intensive chemotherapy and imatinib (IDEAMOP
regimen) for the treatment of newly diagnosed BCR-ABL positive
acute lymphoblastic leukemia; Excellent efficacy without increasing
toxicity. /// Yanada M. Emi N. Usui N. Takeuchi J. Sugiura I.
Takeuchi M. Kobayashi T. Yagasaki F. Ohtake S. Matsuo K. Naoe T.
Ohno R. Japan Adult Leukemia Study Grp /// BLOOD 104
(11):748A-748A 2736 2004
23．P-glycoprotein is related to the achievement of complete
remission but not to disease-free survival in adult acute
lymphoblastic leukemia: A prospective analysis in the
JALSG-ALL97 study /// Takeshita A. Ohnishi K. Miyazaki Y. Jnnai
I. Miyawaki S. Takahashi M. Murakami T. Inoue N. Tanaka J. Asou
N. Kobayashi Y. Ueda R. Ohno R. /// BLOOD 104 (11):311A-311A
1095 2004
22．Postremission treatment with chemotherapy or allogeneic stem
cell transplantation (allo-SCT) in adults with acute myeloid
leukemia (AML) – JALSG AML-97 trial. /// Sakamaki H. Miyawaki
S. Kishimoto Y. Miyazaki Y. Asou N. Ogawa Y. Honda S. Ohno R.
/// BLOOD 104 (11):632A-632A 2298 2004
21．Postremission therapy in adult acute myeloid leukemia (AML): A
randomized comparison of intensified consolidation therapy without
maintenance therapy against conventional consolidation with
maintenance therapy -JALSG AML-97 trial. /// Miyawaki S.
Ohtake S. Yagasaki F. Mitani K. Matsuda S. Kishimoto Y. Miyazaki
Y. Asou N. Ogawa Y. Honda S. Ohno R. /// BLOOD 104
(11):248A-248A 868 2004
20．Validation study on the prediction of response to imatinib mesylate
in chronic myeloid leukemia (CML) patients by genome-wide cDNA
microarray analysis. /// Kagami Y. Katagiri T. Kaneta Y. Tsuruo T.
Nakamura Y. Ohno R. /// BLOOD 104 (11):805A-805A 2946 2004
19．Prospective study of P-glycoprotein, multidrug resistance
associated protein and lung resistance related protein expression
in acute myeloid leukemia treated with the JALSG-AML95
protocol. /// Takeshita A. Shinjo K. Ohnishi K. Miyawaki S.
Kishimoto Y. Okada M. Mitani K. Asou N. Komatsu N. Kobayashi Y.
Jinnai I. Ohtake S. Ueda R. Ohno R. /// BLOOD 102
(11):605A-605A 2233 2003
18．Biological and clinical significance of the FLT3 transcript level in
acute myeloid leukemia. /// Ozeki K. Kiyoi H. Ueda R. Ohno R. Emi
K. Naoe T. /// BLOOD 102 (11):575A-576A 2119 2003
17．Cytogenetic heterogeneity of acute myeloid leukemia with
trilineage dysplasia – JALSG-AML 92 study. /// Tomonaga M.
Kuriyama K. Miyazaki Y. Miyawaki S. Ohtake S. Sakamaki H.
Matsuo T. Emi N. Kobayashi T. Matsushima T. Shinagawa K. Ohno
R. /// BLOOD 100 (11):335A-335A 1298 2002
16．Arsenic trioxide therapy for relapsed or refractory Japanese
patients with acute promyelocytic leukemia /// Shigeno K.
Nakamura S. Naito K. Yoshida H. Fujisawa S. Shinjo K. Fujita Y.
Matsui H. Sahara N. Takeshita A. Ohno R. Ohnishi K. /// BLOOD
100 (11):264B-264B 4583 2002
15．The percentage of myeloperoxidase-positive blast cells is a strong
independent prognostic factor in acute myeloid leukemia, even in
the patients with normal karyotype – JALSG-AML92 study. ///
Miyazaki Y. Matsuo T. Kuriyama K. Yoshida S. Tomonaga M. Emi N.
Kobayashi T. Miyawaki S. Matsushima T. Shinagawa K. Honda S.
Ohno R. /// BLOOD 100 (11):334A-334A 1297 2002
14．Myeloid/NK cell precursor acute leukemia is a distinct subtype of
AML M0. /// Suzuki R. Murata M. Kami M. Ohtake S. Asou N.
Kodera Y. Seto M. Hamajima N. Shimoyama M. Ohno R. Morishima
Y. Nakamura S. /// BLOOD 98 (11):460A-460A 1926 Part 1 2001
13．Multicenter prospective study of interferon-alpha versus bone
marrow transplantation for newly diagnosed patients with chronic
myelogenous leukemia: An interim analysis of the Kouseisho
leukemia study group. /// Ohnishi K. Ino T. Kishimoto Y. Usui N.
Shimazaki C. Ohtake S. Ohno R. /// BLOOD 98 (11):348A-348A
1468 Part 1 2001
12．Standard dose of idarubicin and cytarabine is highly effective
remission induction therapy for the patients with therapy-related
leukemia (TRL): A result of multiinstitutional phase II study. ///
Yokozawa T. Takeyama K. Fukushima T. Uike N. Nagata K. Kagami
Y. Ohno R. Saito H. Ueda R. /// BLOOD 94 (10):298A-298A 1329
Part 1 Suppl. 1 1999
11．Good prognosis of patients with acute promyelocytic leukemia
(APL) who obtained second complete remission (CR) by a new
retinoid, AM80, for relapse from CR induced all -trans retinoic
acid. /// Takeshita A. Naito K. Miyawaki S. Takeuchi M. Ueda R.
Ohno R. /// BLOOD 94 (10):506A-506A 2264 Part 1 Suppl. 1 1999
10．Combination chemotherapy with risk factors-adjusted dose
attenuation for high-risk myelodysplastic syndromes and their
leukemia in the japan adult leukemia study group. /// Okamoto T.
Kanamaru A. Shimazaki C. Motoji T. Takemoto Y. Ohno R. Japan
Luekemia Study Grp /// BLOOD 94 (10):307A-307A 1375 Part 1
Suppl. 1 1999
9．Randomized clinical trial of response-oriented individualized versus
fixed schedule induction chemotherapy in adult acute myeloid
leukemia: The JALSG AML95 study. /// Ohtake S. Miyawaki S.
Tanimoto M. Kuriyama K. Matusda S. Hatake K. Kishimoto Y.
Takemoto Y. Takahashi M. Tamura J. Takeuchi J. Kageyama S.
Kanamaru A. Asou N. Ohno R. /// BLOOD 94 (10):298A-298A
1330 Part 1 Suppl. 1 1999
8．The JALSG APL92 study for newly diagnosed acute promyelocytic
leukemia (APL): Analysis of prognostic factors to increase cure
rate in the next study. /// Ohno R. Asou N. Kanamaru A. Miyawaki
S. Ohtake S. Tomonaga M. /// BLOOD 94 (10):505A-505A 2262
Part 1 Suppl. 1 1999
7．Randomized study of individualized induction therapy with or
without etoposide in adult acute myeloid leukemia (except for M3)
(JALSG-AML92 study) and analysis of prognostic factors. ///
Miyawaki S. Tanimoto M. Kobayashi T. Minami S. Tamura J. Hatake
K. Kuriyama K. Ohmoto E.. Saito K. Kanamaru A. Oho H. Ohtake S.
Jinnai I. Sakamaki H. Yamada O. Asou N. Takahashi M. Takeyama
K. Matsuda S. Ueda R. Ohno R. /// BLOOD 90 (10):2244-2244
Part 1 Suppl. 1 1997
6．JALSG-AML92 for newly diagnosed acute promyelocytic leukemia
(APL) with all-trans retinoic acid (ATRA) followed by intensive
consolidation acid maintenance/intensification chemotherapy:
Prognostic factors for remission and survival /// Ohno R. Asou N.
Kanamaru A. Adachi K. Miyawaki S. Kageyama S. Hiraoka A.
Ohmoto E. Sakamaki H. Tsubaki K. Saito K. Kuriyama K. Oh H.
Kitano Y. /// BLOOD 88 (10):1157-1157 Part 1 Suppl. 1 1996
5．Macrophage-colony stimulating factor (M-CSF) reduces the
incidence and duration of febrile neutropenia and shortens the
period required to finish three courses of intensive consolidation
therapy in acute myeloid leukemia (AML): A double-blind controlled
study /// Ohno R. Miyawaki S. Hatake K. Tomonaga M. Kobayashi
T. Tanimoto M. Masaoka T. Miura Y. Takaku F. Ohashi Y. Motoyoshi
K. /// BLOOD 86 (10):1050-1050 1995
4．Is chemotherapy or HLA-identical sibling bone marrow transplant
better in adults with acute lymphoblastic leukemia (ALL) in first
remission?. /// Oh H. Ohno R. Tanimoto M. Tomonaga M. Murakami
H. Ino T. Zhang MJ. Horowitz MM. Gale RP /// BLOOD 86
(10):2456-2456 Suppl. 1 1995
3．Molecular analysis of the t(15;17) translocation in de novo and
secondary acute promyelocytic leukemia /// Naoe T. Kudo K.
Yoshida H. Horibe K. Ohno, R /// BLOOD 86 (10):2933-2933 1995
2．All-trans-retinoic acid for the treatment of newly-diagnosed acute
promyelocytic leukemia-response /// Kanamaru A. Ohno R. ///
BLOOD 86 (4):1645-1645 1995
1．Randomized trial between behenoyl cytarabine (BHAC) or
cytarabine in combination chemotherapy of adult acute myeloid-
leukemia (AML) (JALSG-AML89 protocol) and analysis of
prognostic factors /// Kobayashi T. Miyawaki S. Tanimoto M.
Kuriyama K. Murakami H. Yoshida M. Kodera Y. Minato K. Tsubaki
K. Ohmoto E. Oh H. Jinnai I. Sakamaki H. Hiraoka A. Kanamaru A.
Takahashi I. Furusawa S. NaoeT. Yamada O. Asou N. Nishikawa K.
Okabe K. Ogura M. Tanaka M. Ohno R. /// BLOOD 84
(10):A146-A146 Suppl. 1 1994